Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Review, H2 2017

 Published On: Oct, 2017 |    No of Pages: 54 |  Published By: Global Markets Direct | Format: PDF
Request Free Sample
Summary

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Islet Amyloid Polypeptide - Pipeline Review, H2 2017, outlays comprehensive information on the Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone. This hormone is released from pancreatic beta cells following food intake to regulate blood glucose levels and act as a satiation signal. It inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle.  The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 3 and 8 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Gastrointestinal, Musculoskeletal Disorders and Central Nervous System which include indications Type 2 Diabetes, Obesity, Type 1 Diabetes (Juvenile Diabetes), Non-Alcoholic Steatohepatitis (NASH), Osteoarthritis, Alzheimer's Disease and Non Alcoholic Fatty Liver Disease (NAFLD).

Furthermore, this report also reviews key players involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP)
- The report reviews Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics and enlists all their major and minor projects
- The report assesses Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and itís most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Overview 7
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 14
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Therapeutics Assessment 16
Assessment by Mechanism of Action 16
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Companies Involved in Therapeutics Development 22
Adocia SAS 22
AstraZeneca Plc 22
Eli Lilly and Co 22
Neurimmune Holding AG 23
Nordic Bioscience A/S 23
Prothena Corp Plc 24
reMYND NV 24
Zealand Pharma AS 25
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drug Profiles 26
(insulin human + pramlintide acetate) - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
(insulin lispro + pramlintide) - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
AC-253 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
DACRA-042 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
DACRA-089 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
KBP-056 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
KBP-088 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Monoclonal Antibodies for Type 2 Diabetes - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
NI-203 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
ReS-39 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Synthetic Peptides to Target IAPP for Obesity and Diabetes - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
UGP-302 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
ZP-4982 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
ZP-5461 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Dormant Products 44
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Discontinued Products 45
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Product Development Milestones 46
Featured News & Press Releases 46
May 11, 2017: Zealand Pharma discloses amylin as the biological target under their 2014 agreement with Boehringer Ingelheim 46
Jan 05, 2017: Adocia Launches New Multi-Hormonal Combination Project For Treatment Of Type 1 Diabetes 46
Jun 08, 2016: Zealand presents new data on proprietary preclinical peptide drug candidates at the 76th Annual American Diabetes Associations Scientific Sessions 47
Aug 19, 2015: Nordic Bioscience Announces Successful Completion of Phase I study for KBP-042 48
May 05, 2014: reMYNDís novel diabetes treatment prevents - and even reverses - disease progression in pre-clinical diabetes models 48
Apr 10, 2013: Centennial Lecture features research on restoring memory and movement 49
Dec 11, 2012: University Of Alberta Medical Researchers Make Key Discovery In Fight Against Alzheimer's Disease 50
Aug 15, 2012: Unigene Labs And Nordic Bioscience Announce Preliminary Selection Of Lead Compound For Treatment Of Type 2 Diabetes 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 53
Disclaimer 54

List of Tables
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Indication, H2 2017 10
Number of Products under Development by Companies, H2 2017 11
Products under Development by Companies, H2 2017 12
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13
Number of Products under Investigation by Universities/Institutes, H2 2017 14
Products under Investigation by Universities/Institutes, H2 2017 15
Number of Products by Stage and Mechanism of Actions, H2 2017 17
Number of Products by Stage and Route of Administration, H2 2017 19
Number of Products by Stage and Molecule Type, H2 2017 21
Pipeline by Adocia SAS, H2 2017 22
Pipeline by AstraZeneca Plc, H2 2017 22
Pipeline by Eli Lilly and Co, H2 2017 23
Pipeline by Neurimmune Holding AG, H2 2017 23
Pipeline by Nordic Bioscience A/S, H2 2017 24
Pipeline by Prothena Corp Plc, H2 2017 24
Pipeline by reMYND NV, H2 2017 25
Pipeline by Zealand Pharma AS, H2 2017 25
Dormant Projects, H2 2017 44
Discontinued Products, H2 2017 45

List of Figures
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Indications, H2 2017 10
Number of Products by Mechanism of Actions, H2 2017 16
Number of Products by Stage and Mechanism of Actions, H2 2017 16
Number of Products by Routes of Administration, H2 2017 18
Number of Products by Stage and Routes of Administration, H2 2017 18
Number of Products by Molecule Types, H2 2017 20
Number of Products by Stage and Molecule Types, H2 2017 20

If the above report does not have the information suitable for your business, we can provide custom research that can be lucrative for your business or enhance your profession.